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Adenocarcinoma of the cervix represents an increasing percentage of cervical cancers 
as well as a controversial clinical problem. One hundred seventy-two cases of adenocarcinoma 
were treated at The University of Michigan Medical Center from 1970 to 1984, representing 
16.8% of cervical cancers. Of this group 84 patients were diagnosed with endocervical 
columnar cell type and form the study population for this report. Survival was influenced 
by stage, grade, and nodal metastases. Age did not influence survival. Survival in stage 1 
disease was not influenced by treatment modality. Radical surgery or radiation therapy 
provided equal survival and ovarian conservation did not adversely influence survival. 
Radical surgery can be considered a primary means of therapy in young women and offers 
the same advantages over radiation therapy as those offered for squamous cell disease. 
0 1987 Academic Press, Inc. 
INTRODUCTION 
Adenocarcinoma of the cervix appears to be increasing from its historic 5% 
of all cervical cancers [I ,2]. Historically it has portended a poorer prognosis in 
all stages than its squamous counterpart [ 11. The treatment of this pathologic 
type of cancer is controversial and prognostic features are still being defined. 
This particular entity has been recognized at The University of Michigan for 
over 50 years. A review of the clinical characteristics and treatment of endocervical 
adenocarcinoma at The University of Michigan Medical Center was undertaken 
for the time period 1970 to 1984 to delineate prognostic features and therapeutic 
alternatives. 
MATERIAL AND METHODS 
The clinical records, pathology reports, and Gynecologic Tumor Conference 
notes for all patients registered at The University of Michigan Medical Center 
Tumor Registry with the diagnosis of adenocarcinoma of the cervix for the time 
period 1970 to 1984 were reviewed. Information was recorded on clinical pres- 
entation, medical history, height, weight, oral contraceptive usage, treatment 
modality, follow-up, grade, and size of cervical lesion. All of the pathologic 
material during this time period had been presented at The Gynecologic Tumor 
’ Presented at the Western Association of Gynecologic Oncologists (WAGO). June 1985. 
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ENDOCERVlCAL ADENOCARCINOMA 
AGE DISTRIBUTION BY DECADE 
FIGURE I 
Conference and reviewed by one of three gynecologic pathologists. Cases where 
pathology was reviewed in consultation only were not included in this study. 
All cases were staged according to International Federation of Gynecologists 
and Obstetricians (FIGO) guidelines. Cases were excluded where the primary 
site could not be differentiated between an endocervical and an endometrial 
origin. 
Statistical analysis was performed by the Department of Biostatistics, School 
of Public Health, University of Michigan. Survival was plotted with the life table 
method described by Kaplan and Meier [3]. The Wilcoxan test was used to test 
difference in survival [4]. A Cox model multivariant regression analysis was used 
to compare hazard for tumor-related death related to potential risk factors [5]. 
A normal approximation (2 score) was used to test the significance of the clinical 
characteristics. 
RESULTS 
During this 1Cyear time period 172 new cases of invasive cervical adenocarcinoma 
were evaluated and treated at The University of Michigan Medical Center. The 
total number of new cases of cervical cancer treated during this time period was 
1072; thus the adenocarcinomas represented 16.8% of the total. Eighty-four of 
these were of the endocervical columnar cell type and form the study population 
for this paper. The remaining 88 were composed of adenosquamous, papillary, 
clear cell, or mucoid type pathology. 
The age distribution was relatively uniform throughout the decades with the 
highest percentage of cases diagnosed in their thirties (Fig. 1). The clinical 
characteristics of the population are presented in Table 1. Patients were classified 
as obese when their weight was 20% above the ideal weight for large frame 
females. Oral contraceptive usage was recorded only for those under 45 years 
old who were using oral contraceptives continuously for 1 or more years at the 
time of diagnosis. 
The majority of the study population (55%) had been examined by a physician 
within 1 year of diagnosis and 68% had been examined within 3 years. The most 
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common presenting symptom (71%) was abnormal bleeding. In those patients 
having cytology, only 60% showed an abnormality. 
Survival analysis was performed for all stages of disease evaluating the effect 
of stage and grade. The overall 5-year survival was 52%. Survival was 58% for 
stages I, II at 7 years. Those patients with advanced disease stages III, IV did 
very poorly with 58% dying within 1 year of diagnosis (P = .OOOl) (Fig. 2). 
Twenty-eight patients with well-differentiated lesions enjoyed a significantly better 
survival advantage over those with a moderate or poorly differentiated tumor 
(P = .0002) (Fig. 3). 
An in situ component, either adeno or squamous in origin, was present in 20% 
of the cases. The presence of this in situ component as an independent finding 
influenced prognosis. Seventeen patients with an in situ component had a 90% 
5-year survival while 67 patients without this component had a 5-year survival 
of approximately 40%. 
A separate survival analysis was then performed on the 68 patients with stage 
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status evaluated independently were both found to significantly influence survival. 
Node status was available in 43 patients and was found to significantly influence 
survival. Thirty-four patients with negative nodes enjoyed an 88% 5-year survival 
while all those with positive nodes were dead of disease by 5 years except one 
who was dead by 7 years. Forty-one patients with lesions less than 3 cm in size 
enjoyed a significant survival advantage (P = 0.0022) over those with lesions 
greater than 3 cm in size. However, when a Cox model multivariant analysis 
evaluating these factors was performed, metastatic disease to the lymph nodes 
was found to be the only significant prognostic factor (Table 2). 
In stage I disease a comparison of treatment modalities was undertaken. The 
cumulative 5year survival was equal for those treated by radiation therapy, 
radical surgery, or combined radiation therapy with extrafascial hysterectomy. 
The poorest survival was in the subgroup of patients treated with radical hys- 
terectomy who then received adjuvant external radiation therapy for factors such 
as metastatic nodal disease, angiolymphatic invasion, or involved surgical margins. 
Eight patients had their ovaries conserved and this did not adversely effect their 
survival compared to the sixteen patients who had their ovaries removed (Table 
3). 
TABLE 2 
AGE, TUMOR SIZE, AND NODE STATUS RELATED TO 
SURVIVAL STAGES I AND II 
Characteristic P value 
Age 0.7621 
Size > 3 cm 0.1226 
Node metastases 0.0016 
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TABLE 3 




Radical hysterectomy 8 100 
Radical hysterectomy + BSO 16 67 
Radical hysterectomy + post-op RT 6 16 
Radiation therapy with extrafacial hysterectomy 7 50 
Radiation therapy 15 62 
DISCUSSION 
Adenocarcinoma is apparently increasing and there is some question whether 
this is an absolute or relative increase secondary to the decrease in invasive 
squamous cell carcinoma. At The University of Michigan Medical Center (UMMC) 
previous reports have shown a 5.5 and 9.6% incidence of adenocarcinoma of 
the cervix [ 1,6]. This report shows a further increase with this neoplasm now 
representing one out of six cases of cervical cancer treated at UMMC. The mean 
number of cases per year has also increased by twofold [Table 41. 
Various subtypes of adenocarcinoma have been reported to influence prognosis 
with the endocervical type being the most favorable [7]. A recent report, however, 
failed to find a difference among subtypes [S]. This study includes only those 
patients with endocervical columnar cell type adenocarcinoma. The 5-year survival 
of 52% for all stages is very similar to the 51% reported for this type from the 
Norwegian Radium Hospital [9]. It is also consistent with the previous 5-year 
survival reported from this institution [l]. The 5-year survival in stage I disease 
of 68% is similar to previous reports from the UMMC of 71%. The survival in 
stage II disease, however, has increased considerably with the use of radiation 
therapy alone and represents an improvement in survival to 58% from 33 and 
25% previously reported from the UMMC [ 1,6]. Unfortunately advanced stages 
III and IV still represent a very poor prognosis with conventional radiation 
therapy offering little hope for salvage. The 9% survival in stage III disease is 
remarkably similar to the 15% survival reported by Abell. No patient with stage 
IV disease in either series has survived [6]. 
A large percentage of the patients were married and had children. Obesity and 
hypertension were not increased over estimates of the national population where 
obesity is 20% and hypertension 26%. The incidence of diabetes is estimated at 
TABLE 4 
MEAN NUMBER OF NEW CASES AND PERCENTAGE OF NEWLY DIAGNOSED CERVICAL ADENOCARCINOMAS 
AT UMMC BY STUDY PERIOD 
Author 
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4% in the national population, and the 8% in the present study population is not 
significantly increased (P = 0.37) [lo]. Oral contraceptive usage has been noted 
with adenocarcinoma [ 11. No study has been done to conclusively show a causal 
relationship and a large case control study evaluating oral contraceptive use as 
a risk factor for all cervical carcinomas failed to show a relationship [ll]. In 
this study population, 47% of married women under 45 years old had used oral 
contraceptives. In 1973 the estimated use of oral contraceptives for married 
females in the U.S. population was 25% [ 121. The difference between this study 
population and the national estimate is not statistically significant (P = 0.28). 
Abnormal bleeding in 71% remains the most common symptom of this disease 
with previous reports showing 74 and 88%. The majority of women in this study 
had normal pelvic exams within 1 to 3 years of diagnosis and almost half had 
normal cytology. The triad of normal exam, normal cytology, and unexplained 
abnormal bleeding appears to be the hallmark of early cervical adenocarcinoma. 
In gynecologic follow-up an endocervical curettage may help detect this abnormality 
in patients with these findings. 
Radical surgery, radiation therapy, or a combined approach offered equal 
survival in this series. The most significant factor influencing prognosis appears 
to be lymph node status. The presence of metastatic disease to lymph nodes is 
a grave prognostic feature and this low survival is similar to that reported by 
Berek et al. [13]. This is in contradistinction to squamous cell metastases in 
lymph nodes where a 60% 5-year survival in stage I disease has been reported 
[ 141. Tumor grade significantly influences prognosis and these results are consistent 
with other reports where well-differentiated adenocarcinoma enjoyed the best 
survival [ 151. 
When analyzed independently size appears to be a significant prognostic factor 
in early stage disease and the lowered survival in this series for lesions greater 
than 3 cm is consistent with previous reports [8,16]. In the multivariant analysis, 
however, the lesion size did not maintain its significance while nodal metastases 
overwhelmingly influenced survival. The presence of nodal metastases may suggest 
systemic disease and be the critical determinant in survival. Thus, the primary 
mode of therapy may need to include systemic therapy when this finding is 
encountered. 
The preservation of ovarian function appears to be reasonable at the time of 
radical hysterectomy. The removal of ovaries did not influence survival and in 
those cases where salpingo-oophorectomy was performed no case of ovarian 
metastases was found. Gallup and Abel1 found metastatic disease to the ovary 
in one of seven patients undergoing radical hysterectomy with bilateral salpingo- 
oophorectomy [ 11. The removal of ovaries in young women undergoing radical 
hysterectomy may not be mandatory, but when preserved careful inspection is 
necessary. 
SUMMARY 
Adenocarcinoma of the cervix appears to be increasing in incidence and represents 
a very real challenge for early diagnosis and improved treatment modalities. 
Early diagnosis is hindered by lack of clinical findings and normal cytologic 
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screening. Survival is influenced by stage at presentation, grade, and presence 
of node metastases. Size by itself is a significant risk factor, but may be less 
important when controlled for lymph node status. Radical hysterectomy, radiation 
therapy, and combined surgery with radiation offered equal survival in stage I 
disease. Ovarian conservation did not adversely influence survival and should 
be considered in young women undergoing radical hysterectomy. Further in- 
vestigation is necessary if survival rates similar to squamous cell disease are to 
be achieved especially in advanced stage disease and in patients with metastatic 
lymph node disease. 
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